Private label ranitidine
This article was originally published in The Tan Sheet
Executive Summary
Joint venture between Ranbaxy Pharmaceuticals and Schein Pharmaceutical to manufacture and market private label ranitidine 75 mg tablets in the U.S. The venture plans to launch the product Dec. 20 after Warner-Lambert's OTC exclusivity for Zantac 75 expires Dec. 19. Other firms that have obtained tentative approvals for private label OTC ranitidine include Granutec, Apotex, Novopharm and Chelsea
Joint venture between Ranbaxy Pharmaceuticals and Schein Pharmaceutical to manufacture and market private label ranitidine 75 mg tablets in the U.S. The venture plans to launch the product Dec. 20 after Warner-Lambert's OTC exclusivity for Zantac 75 expires Dec. 19. Other firms that have obtained tentative approvals for private label OTC ranitidine include Granutec, Apotex, Novopharm and Chelsea. |